Resultados de la búsqueda 171-180 of 12702 for Placental abruption

1. Mayo Clinic Physician Update - October 2025

   Page 1.

2. Hematología - Ensayos clínicos - Mayo Clinic

   This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy ...

3. Mayo Clinic PM&R Physician Update - June 2025

   Page 1.

4. Hematología - Ensayos clínicos - Mayo Clinic

   All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...

5. Mayo Clinic PM&R Physician Update - October 2025

   Page 1.

6. Hematología - Ensayos clínicos - Mayo Clinic

   All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...

7. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   This phase II trial studies the effect of ascorbic acid and combination chemotherapy in treating patients with lymphoma that has come back (recurrent) or ...

8. Mayo Clinic Otolaryngology Physician Update - September 2025

   Page 1.

9. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in ...

10. Hematología - Ensayos clínicos - Mayo Clinic

    All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...